WuXi Biologics (Cayman) (2269) Stock Overview
An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2269 from our risk checks.
2269 Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
WuXi Biologics (Cayman) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$31.08 |
| 52 Week High | HK$44.00 |
| 52 Week Low | HK$23.10 |
| Beta | 0.56 |
| 1 Month Change | -8.21% |
| 3 Month Change | -9.97% |
| 1 Year Change | 11.00% |
| 3 Year Change | -34.50% |
| 5 Year Change | -76.47% |
| Change since IPO | 230.05% |
Recent News & Updates
Narrative Update • Jun 01
2269: Expanding Global CRDMO And Vaccine GMP Platform Will Support Long Term Upside
Analysts have adjusted their price target for WuXi Biologics (Cayman) from HK$45.08 to HK$46.39. This change reflects updated views on its discount rate, revenue growth, profit margin and future P/E assumptions.
Narrative Update • May 13
2269: Capacity Expansion Progress Will Leave Shares Vulnerable To P/E Compression
Analysts have adjusted their view on WuXi Biologics (Cayman), with the implied fair value holding steady at about HK$30.30. Small changes to the discount rate, revenue growth and profit margin assumptions, along with a slightly lower future P/E, offset each other in their updated price target work.Narrative Update • Apr 28
2269: New Partnerships And GMP Progress Will Support A Fairly Valued Outlook
Analysts have trimmed their price target on WuXi Biologics (Cayman) to HK$30.30 from HK$33.34, reflecting updated assumptions that combine slightly lower revenue growth and a reduced future P/E with a marginally higher profit margin outlook and discount rate. What's in the News Structural work is complete and key equipment has arrived at WuXi Biologics' new 95,000 square meter microbial commercial manufacturing site in Chengdu.Recent updates
Narrative Update • Jun 01
2269: Expanding Global CRDMO And Vaccine GMP Platform Will Support Long Term Upside
Analysts have adjusted their price target for WuXi Biologics (Cayman) from HK$45.08 to HK$46.39. This change reflects updated views on its discount rate, revenue growth, profit margin and future P/E assumptions.Narrative Update • May 13
2269: Capacity Expansion Progress Will Leave Shares Vulnerable To P/E Compression
Analysts have adjusted their view on WuXi Biologics (Cayman), with the implied fair value holding steady at about HK$30.30. Small changes to the discount rate, revenue growth and profit margin assumptions, along with a slightly lower future P/E, offset each other in their updated price target work.Narrative Update • Apr 28
2269: New Partnerships And GMP Progress Will Support A Fairly Valued Outlook
Analysts have trimmed their price target on WuXi Biologics (Cayman) to HK$30.30 from HK$33.34, reflecting updated assumptions that combine slightly lower revenue growth and a reduced future P/E with a marginally higher profit margin outlook and discount rate. What's in the News Structural work is complete and key equipment has arrived at WuXi Biologics' new 95,000 square meter microbial commercial manufacturing site in Chengdu.
Narrative Update • Apr 14
2269: New Complex Biologic Collaborations Will Drive Future Upside
Analysts have raised their price target for WuXi Biologics (Cayman) from HK$52.06 to HK$63.73. This reflects updated assumptions around revenue growth, profit margins and future P/E expectations, along with a slightly higher discount rate.Narrative Update • Mar 31
2269: Future Alliances And Compliance Wins Will Support A Fairly Valued Outlook
Analysts have revised their price target for WuXi Biologics (Cayman) to HK$33.34 from HK$32.64, based on updated assumptions for revenue growth, profit margins, future P/E levels and a slightly lower discount rate. What's in the News WuXi Biologics and Earendil Labs signed a collaboration for development and manufacturing of multiple bispecific and multispecific antibodies and ADC candidates, with WuXi Biologics providing end to end services from cell line development through GMP manufacturing to support global clinical development timelines (Client Announcements).Narrative Update • Mar 16
2269: Expanding Bispecific And ADC Partnerships Will Support Long Term Upside Potential
Analysts now set a higher price target for WuXi Biologics (Cayman) at HK$45.08, up from HK$39.83. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.Narrative Update • Mar 02
2269: Future Alliances And Capacity Utilization Will Not Justify Current Price
Analysts have slightly raised their HK$ price target for WuXi Biologics (Cayman). This reflects updated assumptions around revenue growth, profit margins, discount rate and future P/E that leave their fair value estimate largely unchanged overall.Narrative Update • Feb 16
2269: Future Capacity And Alliance Gains Will Not Justify Current Price
Analysts have adjusted their price target for WuXi Biologics (Cayman) to reflect an updated view of fair value at HK$32.52, with slightly revised assumptions on the discount rate, revenue growth, profit margin and future P/E, now at 19.98x. What's in the News Issued unaudited earnings guidance for 2025, with revenue expected at RMB 21.79b and profit attributable to equity shareholders at RMB 4.91b, citing factors such as the Follow and Win the Molecule approach, broader service offerings, use of existing and new capacity including Europe, WBS driven cost savings, and investment gains (Corporate guidance).Narrative Update • Feb 02
2269: Global CRDMO Expansion And New Biologic Partnerships Will Drive Future Upside
Analysts have increased their price target range for WuXi Biologics (Cayman), citing updated assumptions around fair value, revenue growth, profit margins and a slightly lower future P/E multiple as the key drivers of the change. What's in the News WuXi Biologics and Sinorda Biomedicine agreed to work together on SND006, a bispecific antibody for inflammatory bowel disease and other autoimmune conditions.Narrative Update • Jan 19
2269: Future Regulatory And Middle East Expansion Wins Will Not Justify Current Price
Analysts have increased their fair value estimate for WuXi Biologics (Cayman) from HK$28.17 to HK$30.63, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple in their refreshed pricing models. What's in the News Two manufacturing facilities in Wuxi, Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC), received GMP certifications from the UK Medicines and Healthcare products Regulatory Agency for commercial manufacturing of an ophthalmic biologic, following a four day inspection with no critical findings (Regulatory Authority: Compliance).Narrative Update • Jan 05
2269: Middle East CRDMO Expansion Will Support Long Term Upside Potential
Analysts have nudged their price target for WuXi Biologics (Cayman) slightly higher to reflect modest adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. This results in an updated valuation of about $39.83 versus $39.54 previously.Narrative Update • Dec 14
2269: Middle East CRDMO Expansion Will Drive Long Term Upside
Analysts have inched up their price target on WuXi Biologics (Cayman) to approximately $39.54 from about $39.39, citing slightly lower perceived risk, expectations for steady high teens revenue growth, and a modestly improved long term profit margin outlook that more than offsets a marginally lower assumed future P E multiple. What's in the News Signed a strategic Memorandum of Understanding with Qatar Free Zones Authority to establish WuXi Biologics' first integrated CRDMO center in the Middle East.Narrative Update • Nov 29
2269: ESG Achievements and Next-Generation Cell Lines Will Drive Future Upside
Analysts have modestly raised their price target for WuXi Biologics (Cayman), increasing it from ¥38.59 to ¥39.39. This change reflects small upward adjustments to fair value estimates based on updated financial projections.Narrative Update • Nov 15
2269: Commercial Milestone in Europe Will Drive Future Market Success
Narrative Update on WuXi Biologics (Cayman) Analyst Price Target Analysts have slightly lowered their price target for WuXi Biologics (Cayman) from $38.61 to $38.59. This adjustment is attributed to a modest increase in the discount rate, while growth and margin projections remain largely unchanged.Narrative Update • Nov 01
2269: Future Recovery And New Modalities Will Drive Balanced Opportunities And Risks
Analysts have raised their price target for WuXi Biologics (Cayman) from HK$38.19 to HK$38.61. They cite improved profit margins and revenue growth expectations, along with optimism for recovery and long-term growth opportunities.Narrative Update • Oct 17
Antibody Drug Conjugates And Bispecific Projects Will Expand Global Reach
Analysts have modestly raised their price target for WuXi Biologics (Cayman) from HK$38.12 to HK$38.19, citing improving first-half performance and expected long-term growth from new modalities as key factors for the upgrade. Analyst Commentary Recent street research reflects cautiously optimistic sentiment toward WuXi Biologics (Cayman), with revised recommendations and higher price targets indicating improved confidence in the company's prospects.Narrative Update • Oct 03
Antibody Drug Conjugates And Bispecific Projects Will Expand Global Reach
WuXi Biologics (Cayman) received a higher analyst price target, rising from HK$37.16 to HK$38.12. Analysts point to a preliminary first half recovery and optimism about new modalities supporting future growth.Narrative Update • Aug 21
Ireland, US And Singapore Facilities Will Transform Pharmaceutical Pipeline
The increase in WuXi Biologics (Cayman)’s consensus price target reflects improved market sentiment driven by a higher future P/E and a slight uptick in net profit margin, raising the fair value estimate from HK$33.29 to HK$34.82. What's in the News Dundalk, Ireland facility approved by EMA as a commercial manufacturing site, marking first commercial biologic launch from WuXi Biologics' Ireland site and reinforcing its global regulatory compliance with a 100% inspection success rate.Analysis Article • Aug 01
WuXi Biologics (Cayman) Inc.'s (HKG:2269) 26% Jump Shows Its Popularity With Investors
WuXi Biologics (Cayman) Inc. ( HKG:2269 ) shares have continued their recent momentum with a 26% gain in the last month...Analysis Article • Jul 29
An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 31% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, WuXi Biologics (Cayman) fair value estimate is HK$46.40 WuXi...
New Narrative • Feb 09
Follow The Molecule Strategy And Global Expansion Will Secure Future Opportunities
Robust pipeline growth with new projects and North American focus drive future revenue and stabilize amidst geopolitical tensions.Shareholder Returns
| 2269 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | -5.1% | -8.3% | -2.6% |
| 1Y | 11.0% | 0.6% | 3.5% |
Return vs Industry: 2269 exceeded the Hong Kong Life Sciences industry which returned 0.6% over the past year.
Return vs Market: 2269 exceeded the Hong Kong Market which returned 3.5% over the past year.
Price Volatility
| 2269 volatility | |
|---|---|
| 2269 Average Weekly Movement | 6.4% |
| Life Sciences Industry Average Movement | 7.3% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.0% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 2269 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2269's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 13,252 | Chris Chen | www.wuxibiologics.com |
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Tumor Associated Antigens (“TAA”) mAb Technology, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh.
WuXi Biologics (Cayman) Inc. Fundamentals Summary
| 2269 fundamental statistics | |
|---|---|
| Market cap | HK$123.76b |
| Earnings (TTM) | HK$5.69b |
| Revenue (TTM) | HK$25.24b |
22.6x
P/E Ratio5.1x
P/S RatioIs 2269 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2269 income statement (TTM) | |
|---|---|
| Revenue | CN¥21.79b |
| Cost of Revenue | CN¥11.77b |
| Gross Profit | CN¥10.02b |
| Other Expenses | CN¥5.11b |
| Earnings | CN¥4.91b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.19 |
| Gross Margin | 45.98% |
| Net Profit Margin | 22.53% |
| Debt/Equity Ratio | 2.0% |
How did 2269 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/12 09:16 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
WuXi Biologics (Cayman) Inc. is covered by 50 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nithya Balasubramanian | Bernstein |
| Bo Li | BofA Global Research |
| Zhishun Siu | CCB International Securities Limited |